Patent ID: 9110085
Filing Date: 2015-08-18
Classification: C12Q,G01N

Abstract:
1. An in vivo method for testing effectiveness of a treatment for thrombotic thrombocytopenic purpura (TTP) in a subject comprising measuring a level of von Willebrand Factor (VWF) or recombinant VWF cleavage fragments in a blood sample from the subject before and after the treatment, wherein a decrease in the level of ultra-large multimer forms of VWF with a reduced triplet structure or an increase in the level of recombinant VWF fragment with satellite bands after the treatment indicates that the treatment is effective in increasing a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) activity or concentration in vivo in the subject thereby indicating effectiveness of the treatment for TTP.